Start Of Phase I Study For Intranasal Pandemic Influenza Vaccine DeltaFLU

 09.07.2008 05:13   medicalnewstoday.com

Avir Green Hills Biotechnology starts a clinical phase I study with its intranasal vaccine deltaFLU against pandemic influenza. This novel generation of a live-attenuated vaccine based on the deletion of the NS1 gene has shown superior preclinical data. In taking this step, the Viennese biotech company sets yet another milestone in the development of effective and safe vaccines.

World SARS